HC Wainwright Reiterates Buy Rating for Cytokinetics (NASDAQ:CYTK)
Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $120.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 221.20% from the stock’s current price. CYTK has been […]
Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $120.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 221.20% from the stock’s current price. CYTK has been […]
